Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-EDIL3 Polyclonal Antibody

Catalog #:   PHA80301 Specific References (30) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: O43854
Overview

Catalog No.

PHA80301

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human EDIL3 (Asp24-Glu480).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

EDIL3, Integrin-binding protein DEL1, DEL1, Developmentally-regulated endothelial cell locus 1 protein, EGF-like repeat and discoidin I-like domain-containing protein 3

Purification

Purified by antigen affinity column.

Accession

O43854

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with EDIL3 antibody (PHA80301) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 54 kDa
    Observed MW: 54 kDa
References

Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update., PMID:40513285

Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374

Protocol for in-plate staining of clinical peripheral blood mononuclear cell samples for high-throughput analysis via spectral flow cytometry., PMID:40347474

Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma., PMID:39975034

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials., PMID:39746495

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients., PMID:39612757

Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas., PMID:39554029

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma., PMID:39504576

Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans., PMID:39345527

EDIL3 alleviates Mannan-induced psoriatic arthritis by slowing the intracellular glycolysis process in mononuclear-derived dendritic cells., PMID:39289212

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab., PMID:39209453

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer., PMID:39190534

Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors., PMID:39185906

The role of EDIL3 in maintaining cartilage extracellular matrix and inhibiting osteoarthritis development., PMID:38081212

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade., PMID:37728484

Presence of coronary aneurysms during Kawasaki Disease (KD) correlates with lower levels of autoantibodies to both full form and spliced variant of immune regulator Del-1., PMID:37019289

Highly sensitive fluorescent detection of EDIL3 overexpressed exosomes for the diagnosis of triple-negative breast cancer., PMID:35820407

DEL1 protects against chondrocyte apoptosis through integrin binding., PMID:30278915

Developmental endothelial locus-1 (Del-1) antagonizes Interleukin-17-mediated allergic asthma., PMID:29437247

The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway., PMID:29182679

Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors., PMID:27864696

Development of a novel multiplex beads-based assay for autoantibody detection for colorectal cancer diagnosis., PMID:26915739

Developmental endothelial locus-1 attenuates complement-dependent phagocytosis through inhibition of Mac-1-integrin., PMID:24352615

Immune response profiling identifies autoantibodies specific to Moyamoya patients., PMID:23518061

Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium., PMID:22388320

[Expressions of receptor tyrosine kinases mRNA and protein in carcinoma of bladder]., PMID:21906447

The role of adhesion molecules, alpha v beta 3, alpha v beta 5 and their ligands in the tumor cell and endothelial cell adhesion., PMID:18090124

Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF., PMID:15964546

Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models., PMID:15005876

Del1 mediates VSMC adhesion, migration, and proliferation through interaction with integrin alpha(v)beta(3)., PMID:11959660

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-EDIL3 Polyclonal Antibody [PHA80301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only